» Articles » PMID: 35740614

Multiple Components of Protein Homeostasis Pathway Can Be Targeted to Produce Drug Synergies with VCP Inhibitors in Ovarian Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Jun 24
PMID 35740614
Authors
Affiliations
Soon will be listed here.
Abstract

Protein quality control mechanisms play an important role in cancer progression by providing adaptive responses and morphologic stability against genome-wide copy number alterations, aneuploidy, and conformation-altering somatic mutations. This dependency on protein quality control mechanisms creates a vulnerability that may be exploited for therapeutic benefits by targeting components of the protein quality control mechanism. Recently, valosin-containing protein (VCP), also known at p97 AAA-ATPase, has emerged as a druggable target in cancer cells to affect their dependency on protein quality control. Here, we show that VCP inhibitors induce cytotoxicity in several ovarian cancer cell lines and these compounds act synergistically with mifepristone, a drug previously shown to induce an atypical unfolded protein response. Although mifepristone at a clinically achievable dose induces a weak unfolded protein response, it enhances the cytotoxic effects of VCP inhibitor CB-5083. Mechanistically, mifepristone blocks the cytoprotective effect of ATF6 in response to endoplasmic reticulum (ER) stress while activating the cytotoxic effects of ATF4 and CHOP through the HRI (EIF2AK1)-mediated signal transduction pathway. In contrast, CB-5083 activates ATF4 and CHOP through the PERK (EIF2AK3)-mediated signaling pathway. This combination activates ATF4 and CHOP while blocking the adaptive response provided by ATF6, resulting in increased cytotoxic effects and synergistic drug interaction.

Citing Articles

Targeting mitochondrial quality control: new therapeutic strategies for major diseases.

Hong W, Huang H, Zeng X, Duan C Mil Med Res. 2024; 11(1):59.

PMID: 39164792 PMC: 11337860. DOI: 10.1186/s40779-024-00556-1.


Active Estrogen-Succinate Metabolism Promotes Heme Accumulation and Increases the Proliferative and Invasive Potential of Endometrial Cancer Cells.

Lu J, Zhang X, Abudukeyoumu A, Lai Z, Hou D, Wu J Biomolecules. 2023; 13(7).

PMID: 37509133 PMC: 10377129. DOI: 10.3390/biom13071097.


A Novel HOXA10-Associated 5-Gene-Based Prognostic Signature for Stratification of Short-term Survivors of Pancreatic Ductal Adenocarcinoma.

Kisling S, Atri P, Shah A, Cox J, Sharma S, Smith L Clin Cancer Res. 2023; 29(18):3759-3770.

PMID: 37432996 PMC: 10529249. DOI: 10.1158/1078-0432.CCR-23-0825.

References
1.
Armstrong D . Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist. 2002; 7 Suppl 5:20-8. DOI: 10.1634/theoncologist.7-suppl_5-20. View

2.
Kretschmer X, Baldwin W . CAR and PXR: xenosensors of endocrine disrupters?. Chem Biol Interact. 2005; 155(3):111-28. DOI: 10.1016/j.cbi.2005.06.003. View

3.
Liu R, Shi P, Nie Z, Liang H, Zhou Z, Chen W . Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression. Theranostics. 2016; 6(4):533-44. PMC: 4775863. DOI: 10.7150/thno.14315. View

4.
Rutherford S, Lindquist S . Hsp90 as a capacitor for morphological evolution. Nature. 1998; 396(6709):336-42. DOI: 10.1038/24550. View

5.
Luo J, Solimini N, Elledge S . Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009; 136(5):823-37. PMC: 2894612. DOI: 10.1016/j.cell.2009.02.024. View